446 related articles for article (PubMed ID: 29116399)
1. Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.
Mahdjoubi A; Najean M; Lemaitre S; Dureau S; Dendale R; Levy C; Rouic LL; Desjardins L; Cassoux N
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):411-420. PubMed ID: 29116399
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
3. Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma.
Tatsumi T; Yamamoto S; Uehara J; Sugawara T; Baba T; Inoue M; Hata H; Mitamura Y
Graefes Arch Clin Exp Ophthalmol; 2013 May; 251(5):1355-60. PubMed ID: 23250484
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.
Olmos LC; Sayed MS; Moraczewski AL; Gedde SJ; Rosenfeld PJ; Shi W; Feuer WJ; Lee RK
Eye (Lond); 2016 Mar; 30(3):463-72. PubMed ID: 26681145
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic use of bevacizumab to avoid anterior segment neovascularization following proton therapy for uveal melanoma.
Mantel I; Schalenbourg A; Bergin C; Petrovic A; Weber DC; Zografos L
Am J Ophthalmol; 2014 Oct; 158(4):693-701.e2. PubMed ID: 25034116
[TBL] [Abstract][Full Text] [Related]
6. Anti-VEGF intravitreal bevacizumab for radiation-associated neovascular glaucoma.
Nagendran ST; Finger PT
Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):201-7. PubMed ID: 25707045
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: a detailed analysis of tumor and dose-volume parameters.
Mishra KK; Daftari IK; Weinberg V; Cole T; Quivey JM; Castro JR; Phillips TL; Char DH
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):330-6. PubMed ID: 23886415
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy.
Eid TM; Radwan A; el-Manawy W; el-Hawary I
Can J Ophthalmol; 2009 Aug; 44(4):451-6. PubMed ID: 19606170
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up.
Arcieri ES; Paula JS; Jorge R; Barella KA; Arcieri RS; Secches DJ; Costa VP
Acta Ophthalmol; 2015 Feb; 93(1):e1-6. PubMed ID: 24989855
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective two-dose comparative study.
Sasamoto Y; Oshima Y; Miki A; Wakabayashi T; Song D; Matsushita K; Hamasaki T; Nishida K
J Ocul Pharmacol Ther; 2012 Feb; 28(1):41-8. PubMed ID: 21992534
[TBL] [Abstract][Full Text] [Related]
11. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma.
Ehlers JP; Spirn MJ; Lam A; Sivalingam A; Samuel MA; Tasman W
Retina; 2008 May; 28(5):696-702. PubMed ID: 18463512
[TBL] [Abstract][Full Text] [Related]
12. Neovascular glaucoma after proton beam therapy of choroidal melanoma: incidence and risk factors.
Riechardt AI; Pilger D; Cordini D; Seibel I; Gundlach E; Hager A; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2263-2269. PubMed ID: 28721444
[TBL] [Abstract][Full Text] [Related]
13. Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab.
Wittström E; Holmberg H; Hvarfner C; Andréasson S
Eur J Ophthalmol; 2012; 22(4):563-74. PubMed ID: 22139613
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab.
Moraczewski AL; Lee RK; Palmberg PF; Rosenfeld PJ; Feuer WJ
Br J Ophthalmol; 2009 May; 93(5):589-93. PubMed ID: 19074917
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma.
Ciftci S; Sakalar YB; Unlu K; Keklikci U; Caca I; Dogan E
Eur J Ophthalmol; 2009; 19(6):1028-33. PubMed ID: 19882572
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab for neovascular glaucoma.
Vasudev D; Blair MP; Galasso J; Kapur R; Vajaranant T
J Ocul Pharmacol Ther; 2009 Oct; 25(5):453-8. PubMed ID: 19857107
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma.
Parrozzani R; Pilotto E; Dario A; Miglionico G; Midena E
Am J Ophthalmol; 2013 Jan; 155(1):127-133.e2. PubMed ID: 22995029
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Intracameral Bevacizumab for Treatment of Neovascular Glaucoma.
Ha JY; Lee TH; Sung MS; Park SW
Korean J Ophthalmol; 2017 Dec; 31(6):538-547. PubMed ID: 29022296
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcome of Intravitreal Bevacizumab Followed by Ahmed Valve Implantation in the Management of Neovascular Glaucoma.
Tailor R; Kinsella MT; Clarke JC
Semin Ophthalmol; 2018; 33(5):606-612. PubMed ID: 28992424
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial.
Yazdani S; Hendi K; Pakravan M; Mahdavi M; Yaseri M
J Glaucoma; 2009; 18(8):632-7. PubMed ID: 19826393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]